A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV.

COVID-19 vaccines SARS-CoV-2 antibody people with HIV seroconversion

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 22 08 2022
accepted: 31 10 2022
entrez: 28 11 2022
pubmed: 29 11 2022
medline: 29 11 2022
Statut: epublish

Résumé

HIV infection is a significant independent risk factor for severe coronavirus disease 2019 (COVID-19) disease and death. We summarize COVID-19 vaccine responses in people with HIV (PWH). A systematic literature review of studies from January 1, 2020, to March 31, 2022, of COVID-19 vaccine immunogenicity in PWH from multiple databases was performed. Twenty-eight studies from 12 countries were reviewed. While 22 (73%) studies reported high COVID-19 vaccine seroconversion rates in PWH, PWH with lower baseline CD4 counts, CD4/CD8 ratios, or higher baseline viral loads had lower seroconversion rates and immunologic titers. Data on vaccine-induced seroconversion in PWH are reassuring, but more research is needed to evaluate the durability of COVID-19 vaccine responses in PWH.

Identifiants

pubmed: 36438620
doi: 10.1093/ofid/ofac579
pii: ofac579
pmc: PMC9685180
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

ofac579

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

Déclaration de conflit d'intérêts

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Références

Vaccines (Basel). 2021 Dec 09;9(12):
pubmed: 34960204
AIDS. 2021 Sep 1;35(11):1872-1874
pubmed: 33993131
HIV Med. 2022 Feb;23(2):178-185
pubmed: 34632695
Clin Infect Dis. 2022 Apr 9;74(7):1268-1270
pubmed: 34293114
NPJ Vaccines. 2022 Feb 28;7(1):28
pubmed: 35228535
J Med Virol. 2022 May;94(5):2230-2236
pubmed: 35106771
EClinicalMedicine. 2022 Jan;43:101226
pubmed: 34901799
J Immunol Res. 2021 Feb 19;2021:6680337
pubmed: 33644235
Int Immunopharmacol. 2022 Jan;102:108383
pubmed: 34824035
AIDS. 2021 Nov 15;35(14):2399-2401
pubmed: 34261097
Viruses. 2022 Jan 28;14(2):
pubmed: 35215870
Lancet HIV. 2021 Aug;8(8):e474-e485
pubmed: 34153264
HIV Med. 2020 Oct;21(9):567-577
pubmed: 32671970
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Clin Infect Dis. 2022 Aug 24;75(1):e630-e644
pubmed: 35179197
Lancet HIV. 2022 Jul;9(7):e486-e495
pubmed: 35561704
Clin Infect Dis. 2022 Aug 24;75(1):e857-e864
pubmed: 34893824
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
FASEB J. 2021 Mar;35(3):e21409
pubmed: 33577115
J Epidemiol Community Health. 1998 Jun;52(6):377-84
pubmed: 9764259
Vaccine. 2022 Jun 9;40(26):3633-3637
pubmed: 35568588
Lancet Reg Health Eur. 2022 Feb;13:100287
pubmed: 34961855
Clin Microbiol Infect. 2021 Dec;27(12):1851-1855
pubmed: 34438069
Infection. 2022 Jun;50(3):617-623
pubmed: 34694595
AIDS. 2022 Apr 1;36(5):691-695
pubmed: 34999608
JCI Insight. 2022 Apr 8;7(7):
pubmed: 35192543
HIV Med. 2022 May;23(5):558-563
pubmed: 34725907
AIDS. 2022 Mar 15;36(4):F1-F5
pubmed: 35013085
EClinicalMedicine. 2021 Nov;41:101158
pubmed: 34693234
Front Immunol. 2022 Feb 10;12:820126
pubmed: 35222357
Clin Infect Dis. 2022 Aug 24;75(1):e585-e593
pubmed: 35234868
Clin Infect Dis. 2022 Aug 24;75(1):e916-e919
pubmed: 34864962
Clin Infect Dis. 2022 Aug 24;75(1):e552-e563
pubmed: 35366316
AIDS. 2022 Mar 1;36(3):479-481
pubmed: 35084386

Auteurs

Helen M Chun (HM)

Division of Global HIV/TB, Center for Global Health, Atlanta, Georgia, USA.

Kyle Milligan (K)

Division of Global HIV/TB, Center for Global Health, Atlanta, Georgia, USA.
Peraton, Herndon, Virginia, USA.

Elfriede Agyemang (E)

Division of Global HIV/TB, Center for Global Health, Atlanta, Georgia, USA.

Nathan Ford (N)

Global HIV, Viral Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland.

Ajay Rangaraj (A)

Global HIV, Viral Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland.

Shalini Desai (S)

Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Annelies Wilder-Smith (A)

Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Marco Vitoria (M)

Global HIV, Viral Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland.

Isaac Zulu (I)

Division of Global HIV/TB, Center for Global Health, Atlanta, Georgia, USA.

Classifications MeSH